OptimizeRx Corp (OPRX, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. OptimizeRx Corp is a technology solutions company serving the healthcare industry. It is engaged in providing consumer and physician platforms. Its core product offering is OPTIMIZERx and SampleMD software application. OptimizeRx Corp has a market cap of $122.210 million; its shares were traded at around $8.37 with and P/S ratio of 4.71. GuruFocus has detected 2 severe warning signs with OptimizeRx Corp. .
For the last quarter OptimizeRx Corp reported a revenue of $7.38 million, compared with the revenue of $6.58 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $24.6 million, an increase of 16% from last year. For the complete 30-year financial data, please go here.. For the last five years OptimizeRx Corp had an average revenue growth rate of 34.3% a year.
The reported loss per diluted share was 23 cents for the year, compared with the earnings per share of $-0.21 in the previous year. The OptimizeRx Corp had an operating margin of -15.02%, compared with the operating margin of 3.72% a year before. The 10-year historical median operating margin of OptimizeRx Corp is -16.29%. The profitability rank of the company is 3 (out of 10).
At the end of the fiscal year, OptimizeRx Corp has the cash and cash equivalents of $18.9 million, compared with $8.91 million in the previous year. The long term debt was $0.45 million. OptimizeRx Corp has a financial strength rank of 8 (out of 10).
At the current stock price of $8.37, OptimizeRx Corp is traded at 30% discount to its historical median P/S valuation band of $11.95. The P/S ratio of the stock is 4.71, while the historical median P/S ratio is 6.67. The stock lost 38.97% during the past 12 months.
For the complete 20-year historical financial data of OPRX, click here.
